FDA approved contrast agent for the detection of accumulations of the Tau protein

Us regulators approved the use of radioactive compounds, developed by Eli Lilly, for detection of the Tau protein, increased level of which indicates the development of Alzheimer’s disease.

New contrast agents are pertusier F18 (flortaucipir F18) are administered to patients intravenously before performing positron emission tomography of the brain. Development Eli Lilly became the first drug on the market that can be used to identify clusters (tangles) of Tau-protein in the brain. Such neurofibrillary tangles are one of the signs of Alzheimer’s disease.

Safety and efficacy were evaluated in two clinical studies in which five doctors studied and interpreted the images obtained with the introduction of pertusier. Part of the results of interpretation were compared with the pathologist’s report. These studies confirmed that the use of the drug allows high accuracy to determine the presence of neurofibrillary tangles.

Leave a Reply

Your email address will not be published. Required fields are marked *

Releated

For the six months Kurgan “Synthesis” increased revenue by 42%

Revenue of JSC “Sintez” (part of the Allium Group) for 6 months of 2020 has increased by 42% year-on-year to 6,767 billion. Net profit reached 752.9 million roubles that on 23% more than in the same period last year. Export sales grew by 36% year-on-year, exceeding 1 billion rubles, told in the company. Secondary sales […]

Russia confirmed on 5 065 new cases COVID-19

In recent days in Russia identified 5 065 new cases of coronavirus in 83 regions. Died 114 people, fully recovered 6 568 patients. In Moscow confirmed 688 new cases of coronavirus. The average rate of increase of new cases for the first two weeks of August is 0.28%. This figure compares with the first two […]